
Please try another search
After-Hours Stock Movers:
Imara Inc. (Nasdaq: IMRA) 19% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Travere Therapeutics, Inc. (TVTX) 5% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.
Eargo, Inc. (EAR) 3% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).
Amprius Technologies (AMPX) 2% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.
Reata Pharmaceuticals, Inc. (Nasdaq: NASDAQ:RETA) 1% HIGHER; announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.